surmount-1 trial tirzepatide non-diabetic weight loss (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants surmount-1 trial tirzepatide weight loss

Doseresponse effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP- 1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

Patients exploring international options should be aware of tirzepatide availability in Mexico and grey market tirzepatide considerations , though domestic compounded sources typically offer better safety assurances

Important Safety Information, including boxed warning Zepbound (tirzepatide) injection may have serious side effects

There are, however, situations where you should not wait but get a professional assessment

Here is the truth

Fasting insulin: detects insulin resistance that may not yet show up in A1c